Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Platelet-activating factor binding to human platelet membranes.

F H Valone, N M Ruis

Biotechnology and Applied Biochemistry

|October 1, 1986

Summary

Researchers optimized methods to quantify platelet-activating factor (PAF) binding to human platelet membranes. This study identified optimal conditions and characterized the PAF receptor on human platelet membranes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Bispecific Antibody MDX-210 for Treatment of Advanced Ovarian and Breast Cancer.

Methods in molecular medicine·2011

Same author

Transplantation with low-density autologous PBSC prepared with BDS60 for women with Stage II, III and IV breast cancer.

Cytotherapy·2002

Same author

Dendritic cell-based treatment of cancer: closing in on a cellular therapy.

Cancer journal (Sudbury, Mass.)·2002

Same author

Fluorouracil modulation in colorectal cancer: lack of improvement with N -phosphonoacetyl- l -aspartic acid or oral leucovorin or interferon, but enhanced therapeutic index with weekly 24-hour infusion schedule--an Eastern Cooperative Oncology Group/Cancer and Leukemia Group B Study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2001

Same author

Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2000

Same author

Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2000

Area of Science:

Biochemistry
Cell Biology
Pharmacology

Background:

Platelet-activating factor (PAF) is a potent lipid mediator involved in various physiological and pathological processes.
Quantifying PAF binding to platelet membranes is crucial for understanding its mechanism of action.
Previous methods were developed for rabbit platelets, necessitating adaptation for human studies.

Purpose of the Study:

To modify and optimize existing methods for quantifying platelet-activating factor (PAF) binding to human platelet membranes.
To characterize the binding kinetics and receptor properties of PAF on human platelet membranes.

Main Methods:

Human platelet membranes were prepared using the glycerol lysis method.
Polyethylene glycol precipitation was employed to quantify membrane-bound PAF.
Binding assays were conducted under varying buffer conditions (KCl, MgCl2, CaCl2, NaCl) and incubation times/temperatures.
Scatchard analysis was performed to determine receptor number and binding affinity.

Main Results:

Optimal PAF binding occurred in buffers with 3-10 mM KCl and 5-10 mM MgCl2 or CaCl2.
NaCl was less effective than KCl, with concentrations >3 mM inhibiting binding.
Maximal binding was achieved after 60 min at 0°C and was reversible.
Scatchard analysis revealed approximately 10.3 x 10^11 receptors/mg membrane protein with a Kd of 7.6 nM.

Conclusions:

The optimized method allows for reliable quantification of PAF binding to human platelet membranes.
The characterized binding site on human platelet membranes exhibits properties consistent with the PAF receptor.
These findings support the use of this membrane preparation for further studies on PAF receptor interactions.

Related Experiment Videos